Table 1.

Characteristics of the GOLDN study population that participated in the postprandial lipemia (PPL) challenge before and after treatment with fenofibrate160 mg/day by APOE genotype group.

	ε3/ε3	ε4 Carrier	ε2 Carrier	P‡
Pre-Fenofibrate PPL	N=666	N=289	N=117
Age (y)	49.2±17	46.9±15	48.4±16	0.12
Gender (%women)	52%	54%	41%	0.06
Waist Circumference (cm)	96.1±16	96.6±18	98.8±13	0.24
Fasting Triglycerides (FTG) (mg/dL)	131.03±96	142.1±97	155.4±91	0.02
Post-Fenofibrate PPL*	N=454	N=203	N=81
Age (y)	49.7±17	47.5±15	49.0±16	0.27
Gender (%women)	50%	55%	40%	0.06
Waist Circumference (cm)	96.8±16	97.2±17	99.7±13	0.31
Fasting Triglycerides (FTG) (mg/dL)	85.5±51	91.7±50	97.2±48	0.09
Avg % change in FTG	−29.0%	−26.4%	−34.4%	0.05
Fenofibric Acid AUC†	69.5±33	67.0±31	74.8±34	0.20

^*GOLDN participants were given the option to participate in the PPL challenge without fenofibrate or in the PPL challenge before and after 3-weeks daily treatment with 160 mg of fenofibrate. Thus samples in pre-fenofibrate PPL study overlap with those in the post-fenofibrate PPL study but are not exactly the same

^†Area under the serum fenofibric acid concentration curve measured at 0, 3.5 and 6 hours following the dose of fenofibrate taken immediately before the PPL challenge calculated using the trapezoidal rule, unit is arbitrary

^‡P-values were derived from tests of the null hypothesis that no group is different using a one-way anova for continuous traits or the chi-square test for categorical variables